GlobeNewsWire
06 Jul 2026, 12:45 UTC · 2h ago
Amplia Announces Changes to Board's Leadership Roles
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
06 Jul 2026, 12:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The ACCENT trial for narmafotinib achieved a 36% response rate and a median overall survival (mOS) of 11.1 months in advanced pancreatic cancer patients. — Positive clinical trial results for a lead drug candidate in a difficult-to-treat cancer are primary drivers of biotech valuation.
+0.80Amplia is initiating a new Phase 2b study to lay the foundation for a Phase 3 registrational study of narmafotinib. — Progression toward a registrational study increases the probability of regulatory approval and commercialization.
+0.60Jane Bell AM has been appointed as the new Chair of the Board, succeeding Dr. Warwick Tong. — Board leadership changes are generally neutral unless they signal a shift in strategic direction or instability.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company reports successful clinical trial data for narmafotinib and is implementing a strategic board succession plan.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
